ARS Pharmaceuticals (NASDAQ:SPRY) Insider Sarina Tanimoto Sells 12,344 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Sarina Tanimoto sold 12,344 shares of the firm’s stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $14.03, for a total value of $173,186.32. Following the transaction, the insider directly owned 1,285,103 shares of the company’s stock, valued at $18,029,995.09. The trade was a 0.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Sarina Tanimoto also recently made the following trade(s):

• On Wednesday, August 20th, Sarina Tanimoto sold 37,656 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $14.09, for a total value of $530,573.04.

ARS Pharmaceuticals Trading Up 1.8%

NASDAQ:SPRY opened at $14.87 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.98 and a current ratio of 6.17. ARS Pharmaceuticals, Inc. has a one year low of $10.00 and a one year high of $18.90. The business’s 50-day simple moving average is $16.84 and its 200 day simple moving average is $14.35. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of -30.35 and a beta of 0.90.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its earnings results on Wednesday, August 13th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.05). ARS Pharmaceuticals had a negative net margin of 42.74% and a negative return on equity of 21.85%. The company had revenue of $15.72 million for the quarter, compared to the consensus estimate of $12.92 million. As a group, sell-side analysts predict that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ARS Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Bernard Wealth Management Corp. bought a new stake in shares of ARS Pharmaceuticals in the fourth quarter valued at about $27,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of ARS Pharmaceuticals in the first quarter valued at about $37,000. GAMMA Investing LLC lifted its stake in shares of ARS Pharmaceuticals by 4,319.7% in the first quarter. GAMMA Investing LLC now owns 3,359 shares of the company’s stock valued at $420,000 after buying an additional 3,283 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of ARS Pharmaceuticals by 78,100.0% in the first quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company’s stock valued at $49,000 after buying an additional 3,905 shares during the period. Finally, Ameritas Investment Partners Inc. lifted its stake in shares of ARS Pharmaceuticals by 16.1% in the second quarter. Ameritas Investment Partners Inc. now owns 5,598 shares of the company’s stock valued at $98,000 after buying an additional 777 shares during the period. Institutional investors own 68.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen lowered ARS Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, July 26th. One research analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $31.00.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.